Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 619-623

  Nie, Zhe ^a   Perretta, Carin ^a   Erickson, Philip ^a   Margosiak, Stephen ^a   Lu, Jia ^a   Averill, April ^a   Almassy, Robert ^a   Chu, Shaosong ^a  

^a Polaris Pharmaceuticals Inc   (United States)

Author keywords

Anticancer; CK2; Kinase

Indexed keywords

MACROCYCLIC COMPOUND; PROTEIN KINASE INHIBITOR; PYRAZOLO[1,5 A][1,3,5]TRIAZINE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER GROWTH; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50;

ANIMALS; ANTINEOPLASTIC AGENTS; CASEIN KINASE II; CELL LINE, TUMOR; COLONIC NEOPLASMS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MALE; MOLECULAR CONFORMATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

ZEA MAYS;

EID: 38149041702     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.074     Document Type: Article

References (21)

1. Ahmad K.A., Wang G., Slaton J., Unger G., and Ahmed K. Anti-Cancer Drugs 16 (2005) 1037
2. Litchfield D.W. Biochem J. 369 (2003) 1
3. Tawfic S., Yu S., Wang H., Faust R., Davis A., and Ahmed K. Histol. Histopathol. 16 (2001) 573
4. Guerra B., and Issinger O.G. Electrophoresis 20 (1999) 391
5. Saha S., Bardelli A., Buckhaults P., Velculescu V.E., Rago C., St Croix B., Romans K.E., Choti M.A., Lengauer C., Kinzler K.W., and Vogelstein B. Science 294 (2001) 1343
6. Seldin D.C., and Leder P. Science 267 (1995) 894
7. Kelliher M.A., Seldin D.C., and Leder P. EMBO J. 15 (1996) 5160
8. Landesman-Bollag E., Channavajhala P.L., Cardiff R.D., and Seldin D.C. Oncogene 16 (1998) 2965
9. Channavajhala P., and Seldin D.C. Oncogene 21 (2002) 5280
10. Wang G., Unger G., Ahmad K.A., Slaton J.W., and Ahmed K. Mol. Cell. Biochem. 274 (2005) 77
11. Lebrin F., Chambaz EM., and Bianchini L. Oncogene 20 (2001) 2010
12. Yamane K. Cancer Res. 65 (2005) 4362
13. Di Maira G., Salvi M., Arrigoni G., Marin O., Sarno S., Brustolon F., Pinna L.A., and Ruzzene M. Cell Death Differ. 12 (2005) 668
14. Slaton J.W., Unger G.M., Sloper D.T., Davis A.T., and Ahmed K. Mol. Cancer Res. 2 (2004) 712
15. Sarno S., Ruzzene M., Frascella P., Pagano M.A., Meggio F., Zambon A., Mazzorana M., Di Maira G., Lucchini V., and Pinna L.A. Mol. Cell. Biochem. 274 (2005) 69
16. Cozza G., Bonvini P., Zorzi E., Poletto G., Pagano M.A., Sarno S., Donella-Deana A., Zagotto G., Rosolen A., Pinna L.A., Meggio F., and Moro S. J. Med. Chem. 49 (2006) 2363
17. Battistutta R., Mazzorana M., Sarno S., Kazimierczuk Z., Zanotti G., and Pinna L.A. Chem. Biol. 12 (2005) 1211
18. Sarno S., Salvi M., Battistutta R., Zanotti G., and Pinna L.A. Biochim. Biophys. Acta 1754 (2005) 263
19. Zien P., Duncan J.S., Skierski J., Bretner M., Litchfield D.W., and Shugar D. Biochim. Biophys. Acta 1754 (2005) 271
20. Nie Z., Perretta C., Erickson P., Margosiak S., Almassy R., Lu J., Averill A., Yager K.M., and Chu S. Bioorg. Med. Chem. Lett. 17 (2007) 4191
21. MTT cell-based assay was based on the formation and the subsequent colorimetric detection of insoluble purple formazan crystals by the metabolically active cells when tetrazolium salt (MTT reagent) was available in the culture media.